APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Vaccine

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Selected research

Market Analysis & Forecast

Global Meningococcal Vaccine Market Analysis and Forecast 2026-2032

21 December 2025192 pages

Choose your research edition.

Industry ResearchMeningococcal Vaccine Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Vaccine Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Meningococcal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.

Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.

Read the full market overview

In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.

This report presents an overview of global market for Meningococcal Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Meningococcal Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Meningococcal Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Meningococcal Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Meningococcal Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Meningococcal Vaccine sales, projected growth trends, production technology, application and end-user industry.

Meningococcal Vaccine Segment by Company

Novartis

GSK

Merck

CSL

Baxter

JN International Medical Corporation

Serum Institute of India

Bio-Med

China National Biotec Group

Hualan Bio

Walvax

Zhifei

Meningococcal Vaccine Segment by Type

Meningtits A

Polysaccharide Meningtitis AC

Meningitis ACYW

Meningococcal Vaccine Segment by Application

6 Months-15Year

over 3 Year

over 2 Year

over 3 Months

Meningococcal Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Meningococcal Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Meningococcal Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Meningtits A Major Manufacturers Table 3. Polysaccharide Meningtitis AC Major Manufacturers Table 4. Meningitis ACYW Major Manufacturers Table 5. Global Meningococcal Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. 6 Months-15Year Major Manufacturers Table 7. over 3 Year Major Manufacturers Table 8. over 2 Year Major Manufacturers Table 9. over 3 Months Major Manufacturers Table 10. Meningococcal Vaccine Industry Trends Table 11. Meningococcal Vaccine Industry Drivers Table 12. Meningococcal Vaccine Industry Opportunities and Challenges Table 13. Meningococcal Vaccine Industry Restraints Table 14. Global Meningococcal Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Meningococcal Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Meningococcal Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Meningococcal Vaccine Revenue Market Share by Region (2021-2026) Table 18. Global Meningococcal Vaccine Revenue Market Share by Region (2027-2032) Table 19. Global Meningococcal Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (10K Pcs) Table 20. Global Meningococcal Vaccine Sales by Region (2021-2026) & (10K Pcs) Table 21. Global Meningococcal Vaccine Sales by Region (2027-2032) & (10K Pcs) Table 22. Global Meningococcal Vaccine Sales Market Share by Region (2021-2026) Table 23. Global Meningococcal Vaccine Sales Market Share by Region (2027-2032) Table 24. Global Meningococcal Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Meningococcal Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Meningococcal Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Meningococcal Vaccine Sales Market Share by Manufacturers (2021-2026) Table 28. Global Meningococcal Vaccine Sales Price (USD/Pcs) of Manufacturers (2021-2026) Table 29. Global Meningococcal Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Meningococcal Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Meningococcal Vaccine Manufacturers, Product Type & Application Table 32. Global Meningococcal Vaccine Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Meningococcal Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Meningococcal Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Meningococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Meningococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Meningococcal Vaccine Revenue Market Share by Type (2021-2026) Table 39. Global Meningococcal Vaccine Revenue Market Share by Type (2027-2032) Table 40. Global Meningococcal Vaccine Sales by Type 2021 VS 2025 VS 2032 (10K Pcs) Table 41. Global Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 42. Global Meningococcal Vaccine Sales by Type (2027-2032) & (10K Pcs) Table 43. Global Meningococcal Vaccine Sales Market Share by Type (2021-2026) Table 44. Global Meningococcal Vaccine Sales Market Share by Type (2027-2032) Table 45. Global Meningococcal Vaccine Price by Type (2021-2026) & (USD/Pcs) Table 46. Global Meningococcal Vaccine Price by Type (2027-2032) & (USD/Pcs) Table 47. Global Meningococcal Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Meningococcal Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Meningococcal Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Meningococcal Vaccine Revenue Market Share by Application (2021-2026) Table 51. Global Meningococcal Vaccine Revenue Market Share by Application (2027-2032) Table 52. Global Meningococcal Vaccine Sales by Application 2021 VS 2025 VS 2032 (10K Pcs) Table 53. Global Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 54. Global Meningococcal Vaccine Sales by Application (2027-2032) & (10K Pcs) Table 55. Global Meningococcal Vaccine Sales Market Share by Application (2021-2026) Table 56. Global Meningococcal Vaccine Sales Market Share by Application (2027-2032) Table 57. Global Meningococcal Vaccine Price by Application (2021-2026) & (USD/Pcs) Table 58. Global Meningococcal Vaccine Price by Application (2027-2032) & (USD/Pcs) Table 59. Novartis Company Information Table 60. Novartis Business Overview Table 61. Novartis Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 62. Novartis Meningococcal Vaccine Product Portfolio Table 63. Novartis Recent Development Table 64. GSK Company Information Table 65. GSK Business Overview Table 66. GSK Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 67. GSK Meningococcal Vaccine Product Portfolio Table 68. GSK Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 72. Merck Meningococcal Vaccine Product Portfolio Table 73. Merck Recent Development Table 74. CSL Company Information Table 75. CSL Business Overview Table 76. CSL Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 77. CSL Meningococcal Vaccine Product Portfolio Table 78. CSL Recent Development Table 79. Baxter Company Information Table 80. Baxter Business Overview Table 81. Baxter Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 82. Baxter Meningococcal Vaccine Product Portfolio Table 83. Baxter Recent Development Table 84. JN International Medical Corporation Company Information Table 85. JN International Medical Corporation Business Overview Table 86. JN International Medical Corporation Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 87. JN International Medical Corporation Meningococcal Vaccine Product Portfolio Table 88. JN International Medical Corporation Recent Development Table 89. Serum Institute of India Company Information Table 90. Serum Institute of India Business Overview Table 91. Serum Institute of India Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 92. Serum Institute of India Meningococcal Vaccine Product Portfolio Table 93. Serum Institute of India Recent Development Table 94. Bio-Med Company Information Table 95. Bio-Med Business Overview Table 96. Bio-Med Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 97. Bio-Med Meningococcal Vaccine Product Portfolio Table 98. Bio-Med Recent Development Table 99. China National Biotec Group Company Information Table 100. China National Biotec Group Business Overview Table 101. China National Biotec Group Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 102. China National Biotec Group Meningococcal Vaccine Product Portfolio Table 103. China National Biotec Group Recent Development Table 104. Hualan Bio Company Information Table 105. Hualan Bio Business Overview Table 106. Hualan Bio Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 107. Hualan Bio Meningococcal Vaccine Product Portfolio Table 108. Hualan Bio Recent Development Table 109. Walvax Company Information Table 110. Walvax Business Overview Table 111. Walvax Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 112. Walvax Meningococcal Vaccine Product Portfolio Table 113. Walvax Recent Development Table 114. Zhifei Company Information Table 115. Zhifei Business Overview Table 116. Zhifei Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 117. Zhifei Meningococcal Vaccine Product Portfolio Table 118. Zhifei Recent Development Table 119. North America Meningococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 120. North America Meningococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 121. North America Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 122. North America Meningococcal Vaccine Sales by Type (2027-2032) & (10K Pcs) Table 123. North America Meningococcal Vaccine Sales Price by Type (2021-2026) & (USD/Pcs) Table 124. North America Meningococcal Vaccine Sales Price by Type (2027-2032) & (USD/Pcs) Table 125. North America Meningococcal Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 126. North America Meningococcal Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 127. North America Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 128. North America Meningococcal Vaccine Sales by Application (2027-2032) & (10K Pcs) Table 129. North America Meningococcal Vaccine Sales Price by Application (2021-2026) & (USD/Pcs) Table 130. North America Meningococcal Vaccine Sales Price by Application (2027-2032) & (USD/Pcs) Table 131. North America Meningococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Meningococcal Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 133. North America Meningococcal Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 134. North America Meningococcal Vaccine Sales by Country (2021 VS 2025 VS 2032) & (10K Pcs) Table 135. North America Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 136. North America Meningococcal Vaccine Sales by Country (2027-2032) & (10K Pcs) Table 137. North America Meningococcal Vaccine Sales Price by Country (2021-2026) & (USD/Pcs) Table 138. North America Meningococcal Vaccine Sales Price by Country (2027-2032) & (USD/Pcs) Table 139. United States Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 140. Canada Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 141. Mexico Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 142. Europe Meningococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 143. Europe Meningococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 144. Europe Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 145. Europe Meningococcal Vaccine Sales by Type (2027-2032) & (10K Pcs) Table 146. Europe Meningococcal Vaccine Sales Price by Type (2021-2026) & (USD/Pcs) Table 147. Europe Meningococcal Vaccine Sales Price by Type (2027-2032) & (USD/Pcs) Table 148. Europe Meningococcal Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 149. Europe Meningococcal Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 150. Europe Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 151. Europe Meningococcal Vaccine Sales by Application (2027-2032) & (10K Pcs) Table 152. Europe Meningococcal Vaccine Sales Price by Application (2021-2026) & (USD/Pcs) Table 153. Europe Meningococcal Vaccine Sales Price by Application (2027-2032) & (USD/Pcs) Table 154. Europe Meningococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Europe Meningococcal Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 156. Europe Meningococcal Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 157. Europe Meningococcal Vaccine Sales by Country (2021 VS 2025 VS 2032) & (10K Pcs) Table 158. Europe Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 159. Europe Meningococcal Vaccine Sales by Country (2027-2032) & (10K Pcs) Table 160. Europe Meningococcal Vaccine Sales Price by Country (2021-2026) & (USD/Pcs) Table 161. Europe Meningococcal Vaccine Sales Price by Country (2027-2032) & (USD/Pcs) Table 162. Germany Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 163. France Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 164. U.K. Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 165. Italy Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 166. Russia Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 167. Spain Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 168. Netherlands Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 169. Switzerland Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 170. Sweden Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 171. Poland Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 172. China Meningococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 173. China Meningococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 174. China Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 175. China Meningococcal Vaccine Sales by Type (2027-2032) & (10K Pcs) Table 176. China Meningococcal Vaccine Sales Price by Type (2021-2026) & (USD/Pcs) Table 177. China Meningococcal Vaccine Sales Price by Type (2027-2032) & (USD/Pcs) Table 178. China Meningococcal Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 179. China Meningococcal Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 180. China Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 181. China Meningococcal Vaccine Sales by Application (2027-2032) & (10K Pcs) Table 182. China Meningococcal Vaccine Sales Price by Application (2021-2026) & (USD/Pcs) Table 183. China Meningococcal Vaccine Sales Price by Application (2027-2032) & (USD/Pcs) Table 184. Asia Meningococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 185. Asia Meningococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 186. Asia Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 187. Asia Meningococcal Vaccine Sales by Type (2027-2032) & (10K Pcs) Table 188. Asia Meningococcal Vaccine Sales Price by Type (2021-2026) & (USD/Pcs) Table 189. Asia Meningococcal Vaccine Sales Price by Type (2027-2032) & (USD/Pcs) Table 190. Asia Meningococcal Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 191. Asia Meningococcal Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 192. Asia Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 193. Asia Meningococcal Vaccine Sales by Application (2027-2032) & (10K Pcs) Table 194. Asia Meningococcal Vaccine Sales Price by Application (2021-2026) & (USD/Pcs) Table 195. Asia Meningococcal Vaccine Sales Price by Application (2027-2032) & (USD/Pcs) Table 196. Asia Meningococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. Asia Meningococcal Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. Asia Meningococcal Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. Asia Meningococcal Vaccine Sales by Country (2021 VS 2025 VS 2032) & (10K Pcs) Table 200. Asia Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 201. Asia Meningococcal Vaccine Sales by Country (2027-2032) & (10K Pcs) Table 202. Asia Meningococcal Vaccine Sales Price by Country (2021-2026) & (USD/Pcs) Table 203. Asia Meningococcal Vaccine Sales Price by Country (2027-2032) & (USD/Pcs) Table 204. Japan Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 205. South Korea Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 206. India Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 207. Australia Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 208. Taiwan Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 209. Southeast Asia Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 210. SAMEA Meningococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 211. SAMEA Meningococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 212. SAMEA Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 213. SAMEA Meningococcal Vaccine Sales by Type (2027-2032) & (10K Pcs) Table 214. SAMEA Meningococcal Vaccine Sales Price by Type (2021-2026) & (USD/Pcs) Table 215. SAMEA Meningococcal Vaccine Sales Price by Type (2027-2032) & (USD/Pcs) Table 216. SAMEA Meningococcal Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 217. SAMEA Meningococcal Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 218. SAMEA Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 219. SAMEA Meningococcal Vaccine Sales by Application (2027-2032) & (10K Pcs) Table 220. SAMEA Meningococcal Vaccine Sales Price by Application (2021-2026) & (USD/Pcs) Table 221. SAMEA Meningococcal Vaccine Sales Price by Application (2027-2032) & (USD/Pcs) Table 222. SAMEA Meningococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 223. SAMEA Meningococcal Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 224. SAMEA Meningococcal Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 225. SAMEA Meningococcal Vaccine Sales by Country (2021 VS 2025 VS 2032) & (10K Pcs) Table 226. SAMEA Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 227. SAMEA Meningococcal Vaccine Sales by Country (2027-2032) & (10K Pcs) Table 228. SAMEA Meningococcal Vaccine Sales Price by Country (2021-2026) & (USD/Pcs) Table 229. SAMEA Meningococcal Vaccine Sales Price by Country (2027-2032) & (USD/Pcs) Table 230. Brazil Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 231. Argentina Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 232. Chile Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 233. Colombia Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 234. Peru Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 235. Saudi Arabia Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 236. Israel Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 237. UAE Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 238. Turkey Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 239. Iran Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 240. Egypt Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 241. Key Raw Materials Table 242. Raw Materials Key Suppliers Table 243. Meningococcal Vaccine Distributors List Table 244. Meningococcal Vaccine Customers List Table 245. Research Programs/Design for This Report Table 246. Authors List of This Report Table 247. Secondary Sources Table 248. Primary Sources List of Figures Figure 1. Meningococcal Vaccine Image Figure 2. Global Meningococcal Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Meningtits A Image Figure 5. Polysaccharide Meningtitis AC Image Figure 6. Meningitis ACYW Image Figure 7. Global Meningococcal Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Meningococcal Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 9. 6 Months-15Year Image Figure 10. over 3 Year Image Figure 11. over 2 Year Image Figure 12. over 3 Months Image Figure 13. Global Meningococcal Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Meningococcal Vaccine Revenue (2021-2032) & (US$ Million) Figure 15. Global Meningococcal Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Meningococcal Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Meningococcal Vaccine Revenue Market Share by Region (2021-2032) Figure 18. Global Meningococcal Vaccine Sales (2021-2032) & (10K Pcs) Figure 19. Global Meningococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032 (10K Pcs) Figure 20. Global Meningococcal Vaccine Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Meningococcal Vaccine Sales YoY (2021-2032) & (10K Pcs) Figure 22. Europe Meningococcal Vaccine Sales YoY (2021-2032) & (10K Pcs) Figure 23. China Meningococcal Vaccine Sales YoY (2021-2032) & (10K Pcs) Figure 24. Asia (Excluding China) Meningococcal Vaccine Sales YoY (2021-2032) & (10K Pcs) Figure 25. South America, Middle East and Africa Meningococcal Vaccine Sales YoY (2021-2032) & (10K Pcs) Figure 26. Global Meningococcal Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Meningococcal Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Meningococcal Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Meningococcal Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Meningococcal Vaccine Revenue Market Share by Type (2021-2032) Figure 32. Global Meningococcal Vaccine Sales by Type (2021 VS 2025 VS 2032) & (10K Pcs) Figure 33. Global Meningococcal Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Meningococcal Vaccine Sales Market Share by Type (2021-2032) Figure 35. Global Meningococcal Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Meningococcal Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Meningococcal Vaccine Revenue Market Share by Application (2021-2032) Figure 38. Global Meningococcal Vaccine Sales by Application (2021 VS 2025 VS 2032) & (10K Pcs) Figure 39. Global Meningococcal Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Meningococcal Vaccine Sales Market Share by Application (2021-2032) Figure 41. North America Meningococcal Vaccine Revenue Share by Type (2021-2032) Figure 42. North America Meningococcal Vaccine Sales Share by Type (2021-2032) Figure 43. North America Meningococcal Vaccine Revenue Share by Application (2021-2032) Figure 44. North America Meningococcal Vaccine Sales Share by Application (2021-2032) Figure 45. North America Meningococcal Vaccine Revenue Share by Country (2021-2032) Figure 46. North America Meningococcal Vaccine Sales Share by Country (2021-2032) Figure 47. Europe Meningococcal Vaccine Revenue Share by Type (2021-2032) Figure 48. Europe Meningococcal Vaccine Sales Share by Type (2021-2032) Figure 49. Europe Meningococcal Vaccine Revenue Share by Application (2021-2032) Figure 50. Europe Meningococcal Vaccine Sales Share by Application (2021-2032) Figure 51. Europe Meningococcal Vaccine Revenue Share by Country (2021-2032) Figure 52. Europe Meningococcal Vaccine Sales Share by Country (2021-2032) Figure 53. China Meningococcal Vaccine Revenue Share by Type (2021-2032) Figure 54. China Meningococcal Vaccine Sales Share by Type (2021-2032) Figure 55. China Meningococcal Vaccine Revenue Share by Application (2021-2032) Figure 56. China Meningococcal Vaccine Sales Share by Application (2021-2032) Figure 57. Asia Meningococcal Vaccine Revenue Share by Type (2021-2032) Figure 58. Asia Meningococcal Vaccine Sales Share by Type (2021-2032) Figure 59. Asia Meningococcal Vaccine Revenue Share by Application (2021-2032) Figure 60. Asia Meningococcal Vaccine Sales Share by Application (2021-2032) Figure 61. Asia Meningococcal Vaccine Revenue Share by Country (2021-2032) Figure 62. Asia Meningococcal Vaccine Sales Share by Country (2021-2032) Figure 63. SAMEA Meningococcal Vaccine Revenue Share by Type (2021-2032) Figure 64. SAMEA Meningococcal Vaccine Sales Share by Type (2021-2032) Figure 65. SAMEA Meningococcal Vaccine Revenue Share by Application (2021-2032) Figure 66. SAMEA Meningococcal Vaccine Sales Share by Application (2021-2032) Figure 67. SAMEA Meningococcal Vaccine Revenue Share by Country (2021-2032) Figure 68. SAMEA Meningococcal Vaccine Sales Share by Country (2021-2032) Figure 69. Meningococcal Vaccine Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Meningococcal Vaccine Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Meningtits A
  • Polysaccharide Meningtitis AC
  • Meningitis ACYW
Applications
  • 6 Months-15Year
  • over 3 Year
  • over 2 Year
  • over 3 Months
Companies covered
  • Novartis
  • GSK
  • Merck
  • CSL
  • Baxter
  • JN International Medical Corporation
  • Serum Institute of India
  • Bio-Med
  • China National Biotec Group
  • Hualan Bio
  • Walvax
  • Zhifei

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Meningococcal Vaccine Market by Type
  3. 1.2.1 Global Meningococcal Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Meningtits A
  5. 1.2.3 Polysaccharide Meningtitis AC
  6. 1.2.4 Meningitis ACYW
  7. 1.3 Meningococcal Vaccine Market by Application
  8. 1.3.1 Global Meningococcal Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 6 Months-15Year
  10. 1.3.3 over 3 Year
  11. 1.3.4 over 2 Year
  12. 1.3.5 over 3 Months
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Meningococcal Vaccine Market Dynamics
  1. 2.1 Meningococcal Vaccine Industry Trends
  2. 2.2 Meningococcal Vaccine Industry Drivers
  3. 2.3 Meningococcal Vaccine Industry Opportunities and Challenges
  4. 2.4 Meningococcal Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Meningococcal Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Meningococcal Vaccine Revenue by Region
  3. 3.2.1 Global Meningococcal Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Meningococcal Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Meningococcal Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Meningococcal Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Meningococcal Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Meningococcal Vaccine Sales by Region
  9. 3.4.1 Global Meningococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Meningococcal Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Meningococcal Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Meningococcal Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Meningococcal Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Meningococcal Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Meningococcal Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Meningococcal Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Meningococcal Vaccine Sales by Manufacturers
  6. 4.2.1 Global Meningococcal Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Meningococcal Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Meningococcal Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Meningococcal Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Meningococcal Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Meningococcal Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Meningococcal Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Meningococcal Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Meningococcal Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Meningococcal Vaccine Tier 1, Tier 2, and Tier 3
5 Meningococcal Vaccine Market by Type
  1. 5.1 Global Meningococcal Vaccine Revenue by Type
  2. 5.1.1 Global Meningococcal Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Meningococcal Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Meningococcal Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Meningococcal Vaccine Sales by Type
  6. 5.2.1 Global Meningococcal Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Meningococcal Vaccine Sales by Type (2021-2032) & (10K Pcs)
  8. 5.2.3 Global Meningococcal Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Meningococcal Vaccine Price by Type
6 Meningococcal Vaccine Market by Application
  1. 6.1 Global Meningococcal Vaccine Revenue by Application
  2. 6.1.1 Global Meningococcal Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Meningococcal Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Meningococcal Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Meningococcal Vaccine Sales by Application
  6. 6.2.1 Global Meningococcal Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Meningococcal Vaccine Sales by Application (2021-2032) & (10K Pcs)
  8. 6.2.3 Global Meningococcal Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Meningococcal Vaccine Price by Application
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Meningococcal Vaccine Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 GSK
  8. 7.2.1 GSK Company Information
  9. 7.2.2 GSK Business Overview
  10. 7.2.3 GSK Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 GSK Meningococcal Vaccine Product Portfolio
  12. 7.2.5 GSK Recent Developments
  13. 7.3 Merck
  14. 7.3.1 Merck Company Information
  15. 7.3.2 Merck Business Overview
  16. 7.3.3 Merck Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck Meningococcal Vaccine Product Portfolio
  18. 7.3.5 Merck Recent Developments
  19. 7.4 CSL
  20. 7.4.1 CSL Company Information
  21. 7.4.2 CSL Business Overview
  22. 7.4.3 CSL Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 CSL Meningococcal Vaccine Product Portfolio
  24. 7.4.5 CSL Recent Developments
  25. 7.5 Baxter
  26. 7.5.1 Baxter Company Information
  27. 7.5.2 Baxter Business Overview
  28. 7.5.3 Baxter Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Baxter Meningococcal Vaccine Product Portfolio
  30. 7.5.5 Baxter Recent Developments
  31. 7.6 JN International Medical Corporation
  32. 7.6.1 JN International Medical Corporation Company Information
  33. 7.6.2 JN International Medical Corporation Business Overview
  34. 7.6.3 JN International Medical Corporation Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 JN International Medical Corporation Meningococcal Vaccine Product Portfolio
  36. 7.6.5 JN International Medical Corporation Recent Developments
  37. 7.7 Serum Institute of India
  38. 7.7.1 Serum Institute of India Company Information
  39. 7.7.2 Serum Institute of India Business Overview
  40. 7.7.3 Serum Institute of India Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Serum Institute of India Meningococcal Vaccine Product Portfolio
  42. 7.7.5 Serum Institute of India Recent Developments
  43. 7.8 Bio-Med
  44. 7.8.1 Bio-Med Company Information
  45. 7.8.2 Bio-Med Business Overview
  46. 7.8.3 Bio-Med Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Bio-Med Meningococcal Vaccine Product Portfolio
  48. 7.8.5 Bio-Med Recent Developments
  49. 7.9 China National Biotec Group
  50. 7.9.1 China National Biotec Group Company Information
  51. 7.9.2 China National Biotec Group Business Overview
  52. 7.9.3 China National Biotec Group Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 China National Biotec Group Meningococcal Vaccine Product Portfolio
  54. 7.9.5 China National Biotec Group Recent Developments
  55. 7.10 Hualan Bio
  56. 7.10.1 Hualan Bio Company Information
  57. 7.10.2 Hualan Bio Business Overview
  58. 7.10.3 Hualan Bio Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Hualan Bio Meningococcal Vaccine Product Portfolio
  60. 7.10.5 Hualan Bio Recent Developments
  61. 7.11 Walvax
  62. 7.11.1 Walvax Company Information
  63. 7.11.2 Walvax Business Overview
  64. 7.11.3 Walvax Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Walvax Meningococcal Vaccine Product Portfolio
  66. 7.11.5 Walvax Recent Developments
  67. 7.12 Zhifei
  68. 7.12.1 Zhifei Company Information
  69. 7.12.2 Zhifei Business Overview
  70. 7.12.3 Zhifei Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Zhifei Meningococcal Vaccine Product Portfolio
  72. 7.12.5 Zhifei Recent Developments
8 North America
  1. 8.1 North America Meningococcal Vaccine Market Size by Type
  2. 8.1.1 North America Meningococcal Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Meningococcal Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Meningococcal Vaccine Price by Type (2021-2032)
  5. 8.2 North America Meningococcal Vaccine Market Size by Application
  6. 8.2.1 North America Meningococcal Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Meningococcal Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Meningococcal Vaccine Price by Application (2021-2032)
  9. 8.3 North America Meningococcal Vaccine Market Size by Country
  10. 8.3.1 North America Meningococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Meningococcal Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Meningococcal Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Meningococcal Vaccine Market Size by Type
  2. 9.1.1 Europe Meningococcal Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Meningococcal Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Meningococcal Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Meningococcal Vaccine Market Size by Application
  6. 9.2.1 Europe Meningococcal Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Meningococcal Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Meningococcal Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Meningococcal Vaccine Market Size by Country
  10. 9.3.1 Europe Meningococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Meningococcal Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Meningococcal Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Meningococcal Vaccine Market Size by Type
  2. 10.1.1 China Meningococcal Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Meningococcal Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Meningococcal Vaccine Price by Type (2021-2032)
  5. 10.2 China Meningococcal Vaccine Market Size by Application
  6. 10.2.1 China Meningococcal Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Meningococcal Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Meningococcal Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Meningococcal Vaccine Market Size by Type
  2. 11.1.1 Asia Meningococcal Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Meningococcal Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Meningococcal Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Meningococcal Vaccine Market Size by Application
  6. 11.2.1 Asia Meningococcal Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Meningococcal Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Meningococcal Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Meningococcal Vaccine Market Size by Country
  10. 11.3.1 Asia Meningococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Meningococcal Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Meningococcal Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Meningococcal Vaccine Market Size by Type
  2. 12.1.1 SAMEA Meningococcal Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Meningococcal Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Meningococcal Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Meningococcal Vaccine Market Size by Application
  6. 12.2.1 SAMEA Meningococcal Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Meningococcal Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Meningococcal Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Meningococcal Vaccine Market Size by Country
  10. 12.3.1 SAMEA Meningococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Meningococcal Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Meningococcal Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Meningococcal Vaccine Value Chain Analysis
  2. 13.1.1 Meningococcal Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Meningococcal Vaccine Production Mode & Process
  6. 13.2 Meningococcal Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Meningococcal Vaccine Distributors
  9. 13.2.3 Meningococcal Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst